Benznidazole
From Wikipedia, the free encyclopedia
 |
|
|
Benznidazole
|
|
| Systematic (IUPAC) name | |
| N-benzyl-2-(2-nitroimidazol-1-yl)acetamide | |
| Identifiers | |
| CAS number | |
| ATC code | P01 |
| PubChem | |
| Chemical data | |
| Formula | C12H12N4O3 |
| Mol. mass | 260.249 g/mol |
| Pharmacokinetic data | |
| Bioavailability | High |
| Metabolism | Hepatic |
| Half life | 12 hours |
| Excretion | Renal and fecal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Benznidazole (INN, marketed by Hoffman-La Roche under the trade names Rochagan® and Radanil®) is an antiparasitic medication used in the treatment of Chagas disease.
[edit] Side effects
The side effects most commonly associated with benznidazole therapy are rash and gastrointestinal symptoms such as nausea. Rarely, peripheral neuropathy may present after prolonged treatment.
[edit] External links
- (Portuguese) Rochagan® [Patient Information] (PDF). Hoffmann-La Roche. Retrieved on 2006-11-27.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
